1. Home
  2. RMTI vs IVVD Comparison

RMTI vs IVVD Comparison

Compare RMTI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rockwell Medical Inc.

RMTI

Rockwell Medical Inc.

HOLD

Current Price

$0.92

Market Cap

35.1M

Sector

Health Care

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$2.32

Market Cap

692.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMTI
IVVD
Founded
1994
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.1M
692.7M
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
RMTI
IVVD
Price
$0.92
$2.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$2.50
$8.33
AVG Volume (30 Days)
227.0K
12.4M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$75,577,000.00
$50,039,000.00
Revenue This Year
N/A
$103.88
Revenue Next Year
$8.12
$171.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
332.71
52 Week Low
$0.78
$0.35
52 Week High
$2.41
$3.07

Technical Indicators

Market Signals
Indicator
RMTI
IVVD
Relative Strength Index (RSI) 43.56 54.13
Support Level $0.87 $2.15
Resistance Level $0.97 $2.59
Average True Range (ATR) 0.06 0.17
MACD 0.01 -0.02
Stochastic Oscillator 34.62 50.50

Price Performance

Historical Comparison
RMTI
IVVD

About RMTI Rockwell Medical Inc.

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: